Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late ...
Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...
with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillationAcquisition adds a late-stage asset and is aligned with Novartis strategic focus ...
Novartis India Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 2,146.62 Crore) operating in Pharmaceuticals sector. Novartis India Ltd. key Products/Revenue ...
Copyright © 2025 MarketWatch, Inc. All rights reserved.
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback